Meisenheim

Researchers are evaluating the effects of BMS-986368, a FAAH/MAGL inhibitor, on spasticity in people with Multiple Sclerosis (MS). This Phase 2 study aims to assess the drug's efficacy, safety, and tolerability by comparing three different doses of BMS-986368 to a placebo in participants who have experienced MS-related spasticity for at least six months. Participants will receive oral doses of BMS-986368 or placebo at specified times. The study includes four groups: three groups receive different doses of BMS-986368, and one group receives a placebo. Treatment is administered according to a set schedule, and the trial is conducted at multiple centers with a double-blind design to ensure unbiased results. During the study, participants' spasticity levels will be measured using the Total Numeric-transformed Modified Ashworth Scale focusing on the most affected lower limb at week 6. Additional evaluations include safety and tolerability assessments. Participants are monitored throughout the treatment period for changes in spasticity and any side effects. The study includes adults aged 18 to 70 years with specific MS-related disability and spasticity criteria.

Employees working in hospitals often face various stressors that can lead to psychological stress. To address this, programs aimed at building resilience are increasingly offered, but most focus on individual resilience. This study evaluates the Tea(m)Time intervention, which emphasizes strengthening resilience at the team level. The research aims to learn what helps or hinders the implementation of Tea(m)Time and to understand how it supports team resilience in hospital staff. The Tea(m)Time intervention is delivered in two phases. First, team leaders receive training on topics such as healthy leadership, resilience, occupational health and safety, posture, psychological empowerment, agile management, and coaching techniques. After this, teams participate in sessions where each hour begins with self-reflection, followed by assessing and prioritizing stress factors. Teams then collaboratively work on identified problems to find solutions. Participants in both the intervention and control groups complete the FITOR questionnaire, which measures individual, team, and organizational resilience, at three points: before the intervention, at 6 months, and at 12 months. The study involves hospital staff from selected clinics who meet the eligibility criteria. Researchers monitor changes in resilience over time to understand the impact of the Tea(m)Time program.